Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

Journal of Clinical Psychiatry

Volumn 62, Issue 4, 2001, Pages 231-238

  Basson, B R ^a   Kinon, B J ^a   Taylor, C C ^a   Szymanski, K A ^a   Gilmore, J A ^a   Tollefson, G D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; AGE; APPETITE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0035024729     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n0404     Document Type: Article

References (43)

1. Weight changes during treatment with phenothiazine derivatives
2. Drug-produced obesity: Experiences with chlorpromazine, perphenazine and clopenthixol
3. Weight gain induced by clozapine
4. Clozapine and weight gain
5. Weight gain among schizophrenic patients treated with clozapine
6. Clozapine-induced weight gain: Prevalence and clinical relevance
7. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study
8. Extrapyramidal side effects and tolerability of risperidone: A review
9. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
10. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
11. Olanzapine versus haloperidol: Acute-phase results of the international double-blind olanzapine trial
12. Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety
13. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo
14. ICI204, 636, an atypical anti-psychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
15. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors
16. Serotonergic control of the organization of feeding and satiety
17. Manipulation of central nervous system histamine or histaminergic receptors (HI) affects food intake in rats
18. Beitrage zum verlauf des korpergewichtes bei psychosen
19. Clinical biochemical and physiological studies in cases of recurrent schizophrenia
20. Changes in weight in patients receiving a "tranquilizing" drug
21. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics
22. Induction of obesity by psychotropic drugs
23. Weight gain associated with psychotropic drugs
24. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
25. Factors associated with weight gain during olanzapine treatment
26. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
27. Increasing prevalence of overweight among US adults
28. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
29. Weight changes with schizophrenic psychosis and psychotropic drug therapy
30. Weight as a correlate of clinical response to psychotropic drugs
31. Weight changes during treatment with phenothiazine derivatives
32. Clozapine and body mass change
33. Novel antipsychotics: Comparison of weight gain liabilities
34. Radioreceptor binding profile of the atypical antipsychotic olanzapine
35. Steroids and obesity in rats
36. Serum leptin levels increase rapidly after initiation of clozapine therapy
37. Body weight and leptin plasma levels during treatment with antipsychotic drugs
38. Too many chronic mentally disabled patients are too fat
39. Body mass index increase of 58% associated with olanzapine